Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BioCorRx (BICX) Cash from Financing Activities (2016 - 2025)

Historic Cash from Financing Activities for BioCorRx (BICX) over the last 16 years, with Q3 2025 value amounting to $810263.0.

  • BioCorRx's Cash from Financing Activities rose 13198.89% to $810263.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.0 million, marking a year-over-year increase of 6185.68%. This contributed to the annual value of $1.1 million for FY2024, which is 3950.64% down from last year.
  • Latest data reveals that BioCorRx reported Cash from Financing Activities of $810263.0 as of Q3 2025, which was up 13198.89% from $214229.0 recorded in Q2 2025.
  • BioCorRx's 5-year Cash from Financing Activities high stood at $2.2 million for Q1 2021, and its period low was $59158.0 during Q2 2024.
  • Moreover, its 5-year median value for Cash from Financing Activities was $409087.5 (2023), whereas its average is $540287.1.
  • As far as peak fluctuations go, BioCorRx's Cash from Financing Activities skyrocketed by 84212.65% in 2021, and later crashed by 8953.25% in 2024.
  • BioCorRx's Cash from Financing Activities (Quarter) stood at $700000.0 in 2021, then crashed by 35.05% to $454662.0 in 2022, then dropped by 2.64% to $442649.0 in 2023, then fell by 24.29% to $335113.0 in 2024, then skyrocketed by 141.79% to $810263.0 in 2025.
  • Its Cash from Financing Activities was $810263.0 in Q3 2025, compared to $214229.0 in Q2 2025 and $625732.0 in Q1 2025.